ABSTRACT

Pityriasis versicolor (PV), also known as tinea versicolor, is caused by Malassezia species. Clinical features of pityriasis versicolor include either hyperpigmented or hypopigmented finely scaly macules. The most frequently affected sites are the trunk, neck, and proximal extremities. In cases of pathogenicity, Malassezia can directly harm the host via virulence factors or toxins, or indirectly by triggering damaging host responses. The diagnosis typically relies on recognising characteristic clinical features. Due to the wide variability in its clinical presentation, recognising the differential diagnosis is critical. Topical therapies are the primary treatment for PV, encompassing nonspecific antifungal agents like sulphur with salicylic acid, selenium sulphide 2.5%, and zinc pyrithione. Additionally, specific topical antifungal medications with either fungicidal or fungistatic properties may also be incorporated into the topical treatment regimen, such as imidazoles, allylamines, and ciclopirox olamine. Patient education and the promotion of good personal hygiene are pivotal to reduce the risk of recurrence. In this paper, we discuss the pathophysiology, risk factors clinical features, diagnosis, and management as well as prevention of Tinea versicolor. Keywords: Tinea versicolor, Malassezia species, Zinc pyrithione, scaly macules, pathophysiology
Publication date: 01/03/2025

https://ijbpas.com/pdf/2025/March/MS_IJBPAS_2025_8796.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.3.8796